Compare Eversource Energy (D/B/A) Common Stock (ES) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.67 (market cap $24.77B), while Vertex Pharmaceuticals Incorporated trades at $507.99 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× Eversource Energy (D/B/A) Common Stock's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ES | VRTX | |
|---|---|---|
Market Cap | $24.77B | $122.98B |
Volume | 3,738,127 | 1,155,743 |
Sector | Utilities | Health |
52-Week High | $76.21 | $557.96 |
52-Week Low | $63.28 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $54.84B | $117.11B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
